Improving the tolerability of the oral targeted anti-cancer drug pazopanib by food intake (DIET)
Phase of Trial: Phase I
Latest Information Update: 23 Sep 2016
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma; Soft tissue sarcoma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms DIET
- 15 Sep 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
- 15 Sep 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.
- 07 Jun 2016 Results of pharmacokinetic analysis (n=16) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology